Weiss Ratings Reaffirms "Sell (E+)" Rating for Century Therapeutics (NASDAQ:IPSC)

Key Points

• Weiss Ratings has reaffirmed its "sell (E+)" rating for Century Therapeutics (NASDAQ: IPSC), indicating caution regarding the stock's outlook.
• Shares fell to $0.58 with a market capitalization of approximately $49.87 million amid mixed analyst ratings, leading to an average price target of $3.75.
• Institutional investors currently hold 50.20% of the stock, reflecting recent interest from various hedge funds in acquiring positions in Century Therapeutics.

Century Therapeutics (NASDAQ:IPSC - Get Free Report)'s stock had its "sell (e+)" rating restated by investment analysts at Weiss Ratings in a report issued on Friday,Weiss Ratings reports.

Separately, Wall Street Zen downgraded shares of Century Therapeutics from a "hold" rating to a "sell" rating in a research report on Monday. Four investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Century Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $3.75.

Century Therapeutics Stock Performance

Shares of IPSC stock traded down $0.01 during mid-day trading on Friday, hitting $0.58. 879,726 shares of the stock were exchanged, compared to its average volume of 910,404. The stock's fifty day simple moving average is $0.52 and its two-hundred day simple moving average is $0.54. Century Therapeutics has a 12-month low of $0.34 and a 12-month high of $1.83. The stock has a market capitalization of $49.87 million, a price-to-earnings ratio of -1.99 and a beta of 1.78.

Century Therapeutics (NASDAQ:IPSC - Get Free Report) last released its quarterly earnings results on Thursday, August 14th. The company reported ($0.38) EPS for the quarter, hitting the consensus estimate of ($0.38). Century Therapeutics had a negative return on equity of 11.53% and a negative net margin of 19.10%. On average, research analysts expect that Century Therapeutics will post -1.61 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Century Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of IPSC. Prudential Financial Inc. purchased a new position in Century Therapeutics in the 2nd quarter worth about $25,000. Qube Research & Technologies Ltd purchased a new stake in shares of Century Therapeutics in the 2nd quarter valued at approximately $38,000. Y Intercept Hong Kong Ltd acquired a new position in Century Therapeutics in the 2nd quarter worth approximately $50,000. Raymond James Financial Inc. purchased a new stake in shares of Century Therapeutics in the second quarter valued at $51,000. Finally, AQR Capital Management LLC grew its holdings in shares of Century Therapeutics by 358.9% during the first quarter. AQR Capital Management LLC now owns 111,079 shares of the company's stock valued at $53,000 after buying an additional 86,875 shares in the last quarter. 50.20% of the stock is owned by institutional investors and hedge funds.

About Century Therapeutics

Century Therapeutics, Inc, a biotechnology company, engages in the development of genetically engineered allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. Its lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy, under Phase 1 trials targeting CD19 for relapsed, refractory B-cell lymphoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.